Cardinal Health price target raised to $280 from $250 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $280 from $250 and keeps an Outperform rating on the shares. The firm adjusted targets in the drug distributor…
Fiscal Year: July - June
Cardinal Health, Inc. (CAH), listed on the NYSE, has a market capitalization of $59.20B. As of Oct 22, 2026, the stock is trading at $255.64 per share@else an unavailable price , offering investors a clear view of its current market value. Cardinal Health, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 35.36, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Cardinal Health, Inc. also offers a dividend yield of 0.81%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Cardinal Health, Inc. (CAH) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Cardinal Health, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Cardinal Health, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Cardinal Health, Inc. is 13.17, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Cardinal Health, Inc. (CAH) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Cardinal Health, Inc. (CAH) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Cardinal Health, Inc. (CAH) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Cardinal Health, Inc.. To access the full SS Score, consider upgrading your subscription.
Cardinal Health, Inc. is a significant player in the industry sector, with a market capitalization of $59.20B and a competitive P/E ratio of 35.36. Investors should compare these metrics with industry peers to gauge whether Cardinal Health, Inc. is outperforming or underperforming within its sector.
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $280 from $250 and keeps an Outperform rating on the shares. The firm adjusted targets in the drug distributor…
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health (CAH) to $295 from $280 and keeps a Buy rating on the shares.
BofA reiterates Buy ratings on McKesson (MCK) and Cardinal Health (CAH) after both companies announced deals to extend distribution agreements with CVS Health (CVS). The extension of the CVS contracts...
Cardinal Health (CAH) has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health (CVS) through June 30, 2032, reflecting the continuation of Cardinal…
In connection with the renewal, Cardinal Health (CAH) has reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, and its long-term non-GAAP…
DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health...
DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2027 on November 5, prior to the opening of trading on the N...
RBC Capital initiated coverage of Cardinal Health (CAH) with an Outperform rating and $276 price target The firm views the vertical integration of the company’s “higher-growth and higher-margin” servi...
Baird analyst Eric Coldwell raised the firm’s price target on Cardinal Health (CAH) to $274 from $251 and keeps an Outperform rating on the shares.
Citi raised the firm’s price target on Cardinal Health (CAH) to $280 from $265 and keeps a Buy rating on the shares. The firm views the company’s fiscal Q4 report…
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cardinal Health (CAH) to $277 from $245 and keeps an Overweight rating on the shares. The firm is raising…
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $250 from $240 and keeps an Outperform rating on the shares. The firm says management reinforced its positive preview…
UBS raised the firm’s price target on Cardinal Health (CAH) to $280 from $274 and keeps a Buy rating on the shares. Momentum is continuing into FY27, but the focus…
Evercore ISI raised the firm’s price target on Cardinal Health (CAH) to $270 from $265 and keeps an Outperform rating on the shares.
Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $265 from $255 and keeps an Overweight rating on the shares.
Barclays raised the firm’s price target on Cardinal Health (CAH) to $275 from $258 and keeps an Overweight rating on the shares. The firm says Cardinal Health offered a “reasonably…
JPMorgan analyst Lisa Gill raised the firm’s price target on Cardinal Health (CAH) to $260 from $215 and keeps a Neutral rating on the shares post the fiscal Q4 earnings…
TD Cowen analyst Charles Rhyee raised the firm’s price target on Cardinal Health (CAH) to $280 from $275 and keeps a Buy rating on the shares. The firm said they…
Leerink raised the firm’s price target on Cardinal Health (CAH) to $292 from $275 and keeps an Outperform rating on the shares.
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2027 | 3.99B | 9.37% | Projected |
| 2028 | 4.36B | 9.37% | Projected |
| 2029 | 4.77B | 9.37% | Projected |
| 2030 | 5.21B | 9.37% | Projected |
| 2031 | 5.70B | 9.37% | Projected |
| 2032 | 6.16B | 8.00% | Projected |
| 2033 | 6.57B | 6.62% | Projected |
| 2034 | 6.91B | 5.25% | Projected |
| 2035 | 7.18B | 3.87% | Projected |
| 2036 | 7.36B | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2025A | 1.85B | 1.00 | 1.85B |
| 2026A | 4.53B | 1.00 | 4.53B |
| 2027E | 3.99B | 1.08 | Login |
| 2028E | 4.36B | 1.16 | Login |
| 2029E | 4.77B | 1.25 | Login |
| 2030E | 5.21B | 1.35 | Login |
| 2031E | 5.70B | 1.46 | Login |
| 2032E | 6.16B | 1.57 | Login |
| 2033E | 6.57B | 1.70 | Login |
| 2034E | 6.91B | 1.83 | Login |
| 2035E | 7.18B | 1.98 | Login |
| 2036E | 7.36B | 2.13 | Login |
| Terminal | 2.13 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.